Business
Eledon Pharmaceuticals Presents Long-Term Phase 1b Data for Tegoprubart in Kidney Transplant Patients at the American Society of Transplant Surgeons Winter Symposium
Data from eight participants continue to support safety and tolerability profile of tegoprubart Mean eGFR increased over the measurement period, from 67.0 mL/min/1.73 m² at 12 months to 74.2 mL/min/1.73 m² at 24 months IRVINE, Calif., Jan. 23, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that it will present 24-month follow-up data from eight patients enrolled in the Phase 1b trial long-term extension evaluating tegoprubart in kidney transplanta
About this update from Eledon Pharmaceuticals, Inc.
[{"type":"image","alt":"Eledon Pharmaceuticals, Inc.","displaySize":"","headline":null,"caption":"Eledon Pharmaceuticals, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":76,"url":"https://media.zenfs.com/en/globenewswire.com/a724d231d4a058286f024bf497bd49c9"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/fe3DFQlar3TdaQ4TB5I5xg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEwNjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/a724d231d4a058286f024bf497bd49c9","width":300,"height":76}},"lazy":false},{"type":"text","content":"Data from eight participants continue to support safety and tolerability profile of tegoprubart","length":95,"tagName":"p"},{"type":"text","content":"Mean eGFR increased over the measurement period, from 67.0 mL/min/1.73 m² at 12 months to 74.2 mL/min/1.73 m² at 24 months","length":122,"tagName":"p"},{"type":"text","content":"IRVINE, Calif., Jan. 23, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that it will present 24-month follow-up data from eight patients enrolled in the Phase 1b trial long-term extension evaluating tegoprubart in kidney transplantation at the American Society of Transplant Surgeons Winter Symposium, taking place January 23–25, 2026, in Scottsdale, Arizona.","length":408,"tagName":"p"},{"type":"text","content":"There were no episodes of biopsy-proven acute rejection, graft loss, death, new-onset diabetes mellitus, or de novo donor-specific antibody formation during the study period. Mean estimated glomerular filtration rate (eGFR) increased over the measurement period, from 67.0 mL/min/1.73 m² at 12 months to 74.2 mL/min/1.73 m² at 24 months.","length":337,"tagName":"p"},{"type":"text","content":"Details on the poster presentation are below:","length":45,"tagName":"p"},{"type":"text","content":"Title: Long-Term Outcomes of a Phase 1, Single Arm Cohort of De Novo Kidney Transplant Recipients Treated with Tegoprubart, an Anti-CD40L Antibody, as the Core Immunosuppression RegimenPoster: #62Session Title: Poster Session BDate: Friday, January 23, 2026, from 5:45 - 7:15 p.m. PT","length":286,"tagName":"p","attribs":{}},{"type":"text","content":"Following the presentation, a copy of the poster will be available in the Investors section of the Company’s website at https://ir.eledon.com/news-and-events/publications-and-present...